-$0.44 EPS Expected for Heron Therapeutics Inc (HRTX) This Quarter

Analysts expect that Heron Therapeutics Inc (NASDAQ:HRTX) will announce ($0.44) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Heron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.28). Heron Therapeutics reported earnings per share of ($0.97) in the same quarter last year, which suggests a positive year-over-year growth rate of 54.6%. The company is scheduled to report its next earnings report on Tuesday, February 26th.

On average, analysts expect that Heron Therapeutics will report full year earnings of ($2.34) per share for the current financial year, with EPS estimates ranging from ($2.52) to ($2.18). For the next financial year, analysts anticipate that the company will post earnings of ($0.80) per share, with EPS estimates ranging from ($1.44) to $0.03. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.05). Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The business had revenue of $19.79 million for the quarter, compared to analyst estimates of $19.84 million. During the same quarter in the prior year, the company earned ($0.77) earnings per share. The company’s quarterly revenue was up 130.9% on a year-over-year basis.

HRTX has been the subject of a number of recent research reports. Cantor Fitzgerald set a $50.00 price objective on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 30th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “buy” rating and set a $34.00 target price for the company in a research note on Thursday, October 11th. Stifel Nicolaus initiated coverage on shares of Heron Therapeutics in a research note on Thursday, September 13th. They issued a “buy” rating and a $55.00 target price for the company. ValuEngine downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, September 4th. Finally, BidaskClub downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $52.09.

Heron Therapeutics stock opened at $27.88 on Friday. Heron Therapeutics has a one year low of $15.00 and a one year high of $42.90. The stock has a market cap of $2.18 billion, a PE ratio of 7.64 and a beta of 1.48.

In related news, Director Kevin C. Tang sold 2,695,000 shares of the firm’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $35.75, for a total value of $96,346,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $32.07, for a total transaction of $192,420.00. Following the completion of the sale, the vice president now owns 6,000 shares of the company’s stock, valued at $192,420. The disclosure for this sale can be found here. Insiders sold a total of 2,701,494 shares of company stock valued at $96,553,796 over the last quarter. 16.20% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the business. MYDA Advisors LLC acquired a new stake in Heron Therapeutics during the second quarter worth approximately $354,000. FMR LLC lifted its position in Heron Therapeutics by 6.5% during the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after acquiring an additional 693,699 shares during the last quarter. Castleark Management LLC lifted its position in Heron Therapeutics by 237.5% during the second quarter. Castleark Management LLC now owns 201,080 shares of the biotechnology company’s stock worth $7,812,000 after acquiring an additional 141,505 shares during the last quarter. Orbimed Advisors LLC lifted its position in Heron Therapeutics by 15.4% during the second quarter. Orbimed Advisors LLC now owns 1,315,100 shares of the biotechnology company’s stock worth $51,092,000 after acquiring an additional 175,300 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Heron Therapeutics by 21.4% during the second quarter. Northern Trust Corp now owns 762,315 shares of the biotechnology company’s stock worth $29,616,000 after acquiring an additional 134,247 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Read More: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply